Paul Tudor Jones Biomarin Pharmaceutical Inc Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 92,768 shares of BMRN stock, worth $6.03 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
92,768Holding current value
$6.03 Million% of portfolio
0.02%Shares
20 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.48 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.25 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.23 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$903 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$682 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...